Michael Mitchell is the Communication Leader, Global Commercial Strategy Organization (GCSO) and R&D Executive Support within the Janssen R&D Communication team.
Michael is responsible for building and leading the strategic planning, development and implementation of integrated external and internal communication for GCSO, Janssen’s Patient Engagement strategy, as well as providing R&D executive communication support. He has also been instrumental in the launch of Janssen One, the long-term global strategy for the company.
Michael joined Johnson & Johnson in October of 2016. Previously, he was with The Medicines Company for 14 years in a variety of roles of increasing responsibility, including as Value Development Lead for Kengreal (cangrelor), where he was responsible for economics and reimbursement, and market access to prepare for launch of Kengreal in the United States. Prior to that position, Michael was Head of Global Communications where he led investor, employee, and product communication. Michael also held the position of Executive Director of Corporate Affairs and Critical Care Business Manager for Northern New Jersey.
Prior to joining The Medicines Company, Michael advised biotechnology clients at Feinstein Kean Healthcare and started his career at Edelman Healthcare.
He currently serves on the Board of the First Tee of Greater Trenton. Michael also served on the Executive Committee for the American Heart Association (AHA) Morris County Heart Walk, 5K run from 2010 through 2014.
Michael earned his Master’s in Business Administration from Rutgers, The State University of New Jersey and his Bachelor of Science in Health Policy and Management from Providence College.